Nierenzellkarzinom
| Studie | Therapieform | Status | Subinvestigator |
|---|---|---|---|
| SUNNIFORECAST A Phase II, randomized, open-label Study of Nivolumab combined with Ipilimumab vs Sunnitinib Monotherapy in subjects with untreated and advanced (unresectabel or metastatic non-clear Cell Renal Cell Carcinoma) | 1st line | offen | Lorch/ Albers/ Hiester |
| MK3475-564 A Phase III, Randomized, Double-Blind, Placebo-Controlled Clinical Trial of Pembrolizumab (MK-3475) as Monotherapy in the Adjuvant Treatment of Renal Cell Carcinoma Post Nephrectomy (KEYNOTE-564) | adjuvant | offen bis vorauss. 12/2018 | Lorch/ Albers/ Hiester |
| TITAN A phase II single arm clinical trial of a tailored Immuno Therapy Approach with Nivolumab in Subjects with metatstatic or advanced Renal Cell Carcinoma | 2nd line | offen | Lorch/ Albers/ Hiester |